Go Deep
Oncolys BioPharma Inc.
Oncolys BioPharma Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -13,164 | -131.3 | 63.09 | 0.24 | 4,225.44 |
Oncolys BioPharma Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|
| Revenue | 500,000,000.0 | 3,090,000.0 | 28,546,000.0 | 0.0 |
| Net Profit | -347,671,000.0 | -414,482,000.0 | -501,577,000.0 | -811,653,000.0 |
| EPS | — | -14.2 | — | -32.7 |
Oncolys BioPharma Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 28,546,000.0 | 31,384,000.0 | 63,038,000.0 | 976,182,000.0 |
| Net Profit | -2,058,049,000.0 | -1,684,778,000.0 | -1,938,505,000.0 | -1,148,938,000.0 |
| EPS | -80.0 | -77.2 | -108.9 | -66.3 |
Oncolys BioPharma Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 4,555,879,000.0 | 3,198,858,000.0 | 2,040,598,000.0 | 2,650,959,000.0 | — |
| Total Liabilities | 555,910,000.0 | 446,649,000.0 | 566,501,000.0 | 491,690,000.0 | — |
| Total Equity | 3,999,969,000.0 | 2,752,209,000.0 | 1,474,097,000.0 | 2,159,269,000.0 | — |
Owes vs Owns
Oncolys BioPharma Inc. owed ¥0.28 for every ¥1 it owned in Jun 2026, up from ¥0.19 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.28× | 0.12× | 0.14× | 0.28× | 0.19× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Oncolys BioPharma Inc. Assets & Liabilities Breakdown (JPY millions)
What it owns — Dec 2025
Cash & short-term investments 80.7%Receivables 0.7%Other assets 18.1%
How it's funded — Dec 2025
Short-term debt 5.1%Long-term debt 1.5%Payables 1.8%Other liabilities 3.9%Shareholders' equity 87.8%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 3,674.7 | 2,411.0 | 1,532.8 | 1,711.3 |
| Receivables | 31.3 | 0.0 | 0.0 | 0.0 |
| Inventory | 3.9 | 4.6 | 5.3 | 24.2 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 20.9 | 20.9 | 20.9 | 20.9 |
| Other assets | 825.0 | 762.3 | 481.5 | 894.5 |
| Liabilities & equity | ||||
| Short-term debt | 233.3 | 127.8 | 127.8 | 227.8 |
| Long-term debt | 66.7 | 166.7 | 161.1 | 155.5 |
| Payables | 80.3 | 84.2 | 212.2 | 63.8 |
| Other liabilities | 175.7 | 68.0 | 65.4 | 44.6 |
| Shareholders' equity | 4,000.0 | 2,752.2 | 1,474.1 | 2,159.3 |
| Net tangible assets | 4,000.0 | 2,752.2 | 1,474.1 | 2,159.3 |
Oncolys BioPharma Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -1,940,866,000.0 | -2,020,088,000.0 | -1,336,922,000.0 | -1,717,135,000.0 | — |
| Investing Activities | -7,583,000.0 | -4,705,000.0 | -5,392,000.0 | 20,117,000.0 | — |
| Financing Activities | 3,221,897,000.0 | 2,879,444,000.0 | 1,142,542,000.0 | -113,830,000.0 | — |